Introduction
Deception has probably always blighted the probity of scientific and medical research. High-profile examples include suspicions that the work of Gregor Mendel on inheritance, of Robert Millikan on the electron and of Sir Cyril Burt on the relationship between genetics and the Intelligence Quotient contained manipulated data. 1 -5 More recently, there have been several well-documented cases of clinical research misdemeanours, instances of unethical research and publications found to contain false or fabricated data. 6 -11 However, compliance with regulatory requirements and the prevention of any contamination of the database of knowledge depends on the full and accurate reporting of validated data. That is why, for example, in the UK, the pharmaceutical industry 12 Principle 2.10 of the currently accepted international standard of GCP (ICH Efficacy Topic E6 'Guideline for Good Clinical Practice'
Step 5) states, 'All clinical trial information should be recorded, handled and stored in a way that allows its accurate reporting, interpretation and verification.' Moreover, Basic Principle 27 of the Declaration of Helsinki (2000) , the accepted basis for clinical trial ethics, states, 'In publication of the results of research, the investigators are obliged to preserve the accuracy of the results.' Implementation and maintenance of relevant quality assurance and quality control systems for every aspect of a clinical trial are inexorably linked to written Standard Operating Procedures (SOPs), 15 and among these there is a need for procedures to deal with misdemeanours in clinical research. Alarmingly, a recent survey 16 showed that about 10% and 70% of respondents in the pharmaceutical industry/contract research and in National Health Service (NHS)/hospitals/ academia, respectively, did not have pertinent SOPs to deal with this crucial issue. This situation requires urgent attention. Moreover, although the independent whistleblower 17 is a significant source of information about clinical research misdemeanours, it is worrying that few countries have arrangements, systems or laws which facilitate or protect good-faith disclosures.
This article briefly considers the disparate attempts of countries to define the meaning of a research misdemeanour, the whistleblower's classic quandary and some national approaches to improving and maintaining research probity. In particular, several interesting developments in the UK are highlighted.
Clinical research misdemeanours: dishonesty, misconduct and fraud
Although it involves an act that gains an unjust advantage and/or harms the rights of others, there is no one single entity that describes the spectrum of misdeeds which constitutes a clinical research misdemeanour. It may range from careless working practices, an innocent mistake due to ignorance, negligence, falsifying data, plagiarism, a dangerous or negligent deviation from accepted practice to serious deliberate fraud. Although many national and professional organizations 18 -21 have attempted allembracing explanations or proposed broad descriptions to incorporate such misdeeds, there is no one internationally accepted definition.
Individual countries use different models. For example, in the Nordic countries, a research misdemeanour has been characterized in a general way as dishonesty. In this region, formal inflexible definitions are not considered critical with a researcher's particular errant behaviour being judged by experienced independent researchers using 'sound judgement'. 21, 22 The US Commission of Research Integrity 23 adopted the term 'research misconduct' with three main types of misconduct being identified (i.e. misappropriation, interference and misrepresentation) and with each being defined. 24 The term 'misconduct' is also preferred in the UK, but although a broad definition has recently been promulgated (i.e. 'Behaviour by a researcher, intentional or not, that falls short of good ethical and scientific standards' 25 ), it has been criticized as being so vague, non-specific and all-encompassing that it is unworkable in the absence of related definitions and procedures. 26 The earlier MRC definition of misconduct is more specific and pragmatically excludes an honest error that may occur through misunderstanding, incompetence or ignorance. In France, the national institute responsible for biomedical research (INSERM) also uses the term misconduct and has adopted its own broad definition. 27 Skewing the scientific database is not in itself a criminal offence. However, fraud is a component of specific criminal offences that might be perpetrated in the clinical research setting, e.g. entering a patient into a clinical study after forging their consent form. 28, 29 Since criminal proceedings may take years, the preferred option has been to report alleged fraud to the controlling professional body or to the institution of the accused so that professional sanctions may be imposed, if appropriate.
The whistleblower
The term 'whistleblower' has negative overtones. It often characterizes a witness of an alleged wrong-doing who becomes an informant to some authority as a 'busybody', a 'troublemaker' or someone who has betrayed their organization and/or their colleagues. Unsurprisingly, being a whistleblower involves personal moral conflicts between a need to express individual autonomy by exposing deception, corruption or fraud, and the fear of being the victim of unfair treatment or punishment. For example, an unsupportive senior researcher or supervisor might try to bully a junior into silence while colleagues might exude debilitating animosity towards a whistleblower. In addition, a discreditable employer may use diversionary tactics to deflect the actual veracity of any disclosure in an attempt to enfeeble the whistleblower's case. Suffering such victimization often results in complex long-lasting emotional, psychological, sociological and economic consequences including isolation, humiliation, character assassination, abuse, suspension or dismissal. 30 -34 Recent wellknown UK examples include that of Stephen Bolsin, the anaesthetist whistleblower at the Bristol Royal Infirmary, 35, 36 who claimed to have been shunned by the medical establishment and was then forced to seek a job abroad, 37, 38 and that of Andrew Millar, who was sacked after alleging malpractice within British Biotechnology by going to the media with his story. 39 Clearly, the genuine whistleblower deserves a better fate.
Measures to manage research misdemeanours and to protect the whistleblower THE NORDIC REGION
Legislation empowered the Danish Ministry of Research to establish three official committees, the Danish Committees on Scientific Dishonesty (DCSD) 40, 41 chaired by a high-court judge. Each committee is composed of independent researchers experienced in the field in which the complaint of scientific dishonesty has been made. 41 The DCSD cannot make any binding decision but submits its report to the employing institution of the accused, a relevant public authority and/or the police, as applicable. For anyone found guilty of scientific dishonesty, dismissal and/or being banned from participating in future research are sanctions that an institution may impose. 21, 42 Although no specific law exists, procedures attempt to protect the whistleblower from being unfairly victimized. For example, a whistleblower may make a discrete complaint to their institution, after which only a limited number of people are allowed to know their identity.
Following 21 where a National Expert Committee was formed in 1997.
Finland differs from other Nordic countries by having a decentralized system. Here, guidelines for use by local university and institutional committees are provided by the National Research Ethics Council. 43 Each local committee reports their findings to the senior executive of its own research organization who then decides on any necessary action against an alleged miscreant.
In the Nordic region, there is no generalized law to protect the whistleblower.
FRANCE
INSERM established a committee on scientific integrity in 1999 44 that investigates allegations of misconduct. Although French citizens have a general duty to report any unlawful act of which they become aware, no specific law exists to protect a whistleblower. However, legislation has recently been introduced to deal with the offence of 'moral harassment' in the workplace, and this might be used to deal with whistleblower victimization. 45 
GERMANY
The vast majority of German universities and scientific research institutions are either state maintained or receive government funding, and each has its own investigative committee. Eligibility for financial support has been linked to the implementation of institutional procedures promoting good scientific practices, 46 and it has been proposed that a national quality-control panel be established to perform random checks on clinical researchers. 47 Although there is no general rule to protect the whistleblower, it has been suggested that local ombudspersons be appointed to confidentially advise whistleblowers, examine their credibility and pursue allegations of research misdemeanours. 48 
USA
The Food and Drug Administration (FDA) regulates scientific studies in human subjects that are designed to develop evidence of the safety and efficacy of investigational drugs, biological products or medical devices. Its authority derives from the Federal Food, Drug, and Cosmetic Act (1938) as supplemented by subsequent amendments, 49 with GCP regulations being established by 50 All parties involved in biomedical research are encouraged to report promptly any breaches of GCP, scientific misconduct or negligent actions by researchers. The FDA does not use the term 'whistleblower' in its database and has no explicit regulations regarding those who report misconduct.
Subject to applicable regulations, the good-faith whistleblower is entitled to receive conditional legal protection against retaliation 51 if they disclose (to the Office of Research Integrity) allegations of scientific misconduct in research being funded by the US Public Health Services. Moreover, a private citizen may also seek to expose false or fraudulent claims for federal funds by bringing a so-called 'Qui Tam' suit. As a
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reward for being a whistleblower (also termed a 'relator'), they receive a significant proportion of any recovered funds while also being entitled to protection against retaliation. 52
UK
Employees of the MRC are obliged to report observed, suspected or apparent scientific misconduct to their MRC Director. If appropriate, the Director appoints an Investigation Committee which ultimately prepares a report. The Director then makes a decision about appropriate sanctions, which includes withdrawal of research funding or dismissal. The Director is required to protect the position and reputation of the whistleblower (termed a 'complainant') whose allegations are made in good faith and to act against those who victimize complainants. 20 A group of UK medical journal editors formed the Committee on Publication Ethics (COPE) 53 to receive information from the editors of affiliated biomedical journals on cases of possible research misconduct. To date, information on 106 cases where evidence of misconduct was found has been published (sources of information are not disclosed). 10 Although COPE remains a most worthy action group, it does not represent a broad cross-section of stakeholders in clinical research and has no powers of regulation or enforcement. Meanwhile, the Department of Health has been implementing a model framework 54 for the governance of research. Appropriate systems are being put in place to detect and address fraud, as well as other scientific or professional misconduct by NHS staff, and to facilitate and support whistleblowers. 55 Although the UK General Medical Council (GMC) has statutory powers, 56 it has no authority to monitor or audit the probity of a medical practitioner's research performance. Moreover, the GMC cannot investigate allegations of a misdemeanour without a formal complaint and also has no mandate to hold non-medically qualified researchers to account. Once a complaint is received, only serious disciplinary matters are referred to the GMC's Professional Conduct Committee for adjudication. However, the outcome may be confounded by the lack of a commonly understood working definition for 'serious professional misconduct'. 57 It is not surprising, therefore, that the record of the GMC in dealing with research misdemeanours reported to them appears to be lamentably feeble compared with the potential extent of the problem. 58 This highlights the need to establish an effective process to deal with medical and nonmedical miscreants.
It has been suggested that a national agency 58 be established to receive good-faith disclosures about suspicions, to have legal powers to identify through inspection, to investigate and, where appropriate, to prosecute medically and non-medically qualified miscreants under criminal law, for research misconduct or fraud. When EU Directive 2001/20/EC is incorporated into UK law, the possibility exists that the Medicines Control Agency (MCA) might be the agency made responsible and/or be made a 'Prescribed Person'/Regulator to receive disclosures by whistleblowers. 59 This scheme could be funded by fees collected from organizations seeking regulatory approval to perform clinical research. In parallel, a proposal has been made for the mandatory education and continuing accreditation of all clinical trial investigators. This would be achieved through an independent national multidisciplinary 'Executive of Research Probity' with legal, ethical, scientific and medical expertise. 55 In addition to promoting SI Ankier Misdemeanours in clinical research: an international problem best research practice, establishing strict codes of practice and nurturing a sympathetic culture towards whistleblowing, organizations involved in clinical research might be approved, with their continued registration being dependent on satisfactory regular inspections.
Another suggestion 60 is to establish a 'National Panel for Research Integrity' (NPRI), the role of which would include the education of researchers and supervisors as well as the development and maintenance of standards. Accreditation of research would not be a remit, but it is proposed that the NPRI would be available to provide advice or to perform confidential external investigation of allegations or suspicions of research misconduct.
The UK has propitious whistleblowing legislation that conditionally protects a goodfaith employee from victimization or dismissal by an employer. 61 Such statutory legislation helps protect the whistleblower in any organization involved in clinical research that lacks adequate internal SOPs to deal with research misdemeanours or where the abuse of established procedures occurs. However, the Act places the onus on the witness to disclose specified categories of malpractice (which includes acts of research misconduct) to defined recipients under specified circumstances. These complexities mean that without proper legal guidance and in the absence of a specialist knowledge of GCP, research misdemeanours may go unrecognized or unreported.
Conclusions
Regardless of the lack of a ubiquitous definition, each instance of clinical research dishonesty, misconduct and/or fraud has the same potential to pervert the research process, compromise patient safety and/or lead to a loss of public confidence in the clinical research process. Whereas fraud is recognizable as a criminal act by all nations, there are no international rules that harmonize the management and regulation of clinical research dishonesty or misconduct. Countries have adopted their own approaches with, for example, Denmark, Norway and Sweden having a centralized and Finland a decentralized system, and with scientific dishonesty being judged as unacceptable in the opinion of leaders in the scientific community. In the USA, where most of biomedical research funding comes from the government, biomedical misconduct is defined and transgressions come under the aegis of federal law.
The system is less well developed in several other countries, including the UK, where there is no accepted definition of research misconduct or a responsible national agency to deal with violations. Nevertheless, under the UK Medicines Act 1968, there is a legal duty to inform the MCA of certain matters, such as safety information, which cast doubt on the continued validity of a Clinical Trial Certificate or a Clinical Trial Certificate Exemption, or findings that might raise safety issues about a Product Licence. 62 This might be the situation if it was discovered that research data had been fabricated or falsified. Then only the GMC has statutory powers to sanction medical practitioners for serious professional misconduct if they receive a complaint, while for non-medically qualified researchers there may be no organization to which concerns of misconduct may be addressed. Meanwhile, details of the relevant legal framework and subsequent implementation of the role of the MCA are awaited with calls also having been made for the establishment of a national multidisciplinary 'Executive of Research Probity' or a 'National Panel for Research Integrity'.
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Research misdemeanours may be identified by routine sponsor monitoring procedures, but it is often a whistleblower who makes an important disclosure. Indeed, for a good-faith whistleblower not to speak out when they have genuine serious concerns may be both unethical and a failure of a professional duty of care. Hence, any organization involved in clinical research must implement clear policies and follow SOPs that encourage and protect good-faith disclosures, deter false and malicious accusations, and ensure that the accused researcher is not automatically stigmatized. 63 A whistleblower's burden may be further eased by protective legislation, such as that which already exists in the UK. Even then, the law by itself will not protect the whistleblower from psychological and social detriments, and there is a need for personal attitudes and institutional culture to be much more sympathetic towards those who voice good-faith concerns with the intention of correcting a misdemeanour. In this respect, the role of the whistleblower must be more clearly recognized as central to the promotion of clinical research probity, individual responsibility and organizational accountability.
There remains a need to establish an international harmonized approach to the management of clinical research misdemeanours and to protect genuine whistleblowers who expose dishonesty, misconduct and fraud in clinical research. 
